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GABAC receptors contain r subunits and mediate feedback in-
hibition from retinal amacrine cells to bipolar cells. We previously
identified the cytoskeletal protein MAP1B as a r1 subunit an-
choring protein. Here, we analyze the structural basis and func-
tional significance of the MAP1B-r1 interaction. Twelve amino
acids at the C terminus of the large intracellular loop of r1 (and
also r2) are sufficient for interaction with MAP1B. Disruption of
the MAP1B-r interaction in bipolar cells in retinal slices de-
creased the EC50 of their GABAC receptors, doubling the recep-
tors’ current at low GABA concentrations without affecting their
maximum current at high concentrations. Thus, anchoring to the
cytoskeleton lowers the sensitivity of GABAC receptors and pro-
vides a likely site for functional modulation of GABAC receptor-
mediated inhibition.
Key words: GABA; r subunit; MAP1B; EC50; retina; bipolar;
uptake
Ionotropic g-aminobutyric acid receptors are divided into two
classes, GABAA and GABAC, both of which gate chloride channels
but have different properties and expression patterns (Rabow et al.,
1995; Lukasiewicz, 1996). GABAC receptors are present mainly in
the retina, with lower levels in the brain and spinal cord (Cutting et
al., 1991; Feigenspan et al., 1993; Qian and Dowling, 1993; Enz et
al., 1995; Ogurusu et al., 1995). They are enriched on retinal
bipolar cell axon terminals where they receive GABAergic input
from amacrine cells (Tachibana and Kaneko, 1987; Feigenspan et
al., 1993). GABAC receptor activation inhibits release of glutamate
from bipolar cells onto retinal ganglion and amacrine cells and
tunes the dynamic range, temporal resolution, and spatial contrast
of retinal responses to visual stimuli (Pan and Lipton, 1995; Dong
and Werblin, 1998; Euler and Masland, 2000; Shields et al., 2000).
GABAA receptors are hetero-oligomers, formed from a1–6,
b1–3, g1–3, d, e, p, and u subunits (Rabow et al., 1995; Bonnert et
al., 1999), whereas GABAC receptors contain distinct r subunits
that, when expressed in Xenopus oocytes, exhibit properties similar
to those of retinal GABAC receptors (Shimada et al., 1992; Fei-
genspan et al., 1993; Wang et al., 1994). Three r subunits have been
cloned that can form functional homo-oligomeric receptors (Cut-
ting et al., 1991; Wang et al., 1994; Shingai et al., 1996) but may also
form hetero-oligomers with each other or with some GABAA
receptor subunits (Zhang et al., 1995; Hackam et al., 1997; Qian
and Ripps, 1999). Clustering of r subunits occurs at synapses on
bipolar axon terminals (Enz et al., 1996; Koulen et al., 1998). We
previously reported an interaction between r1 and the
microtubule-associated protein MAP1B (heavy chain) as a likely
mechanism for anchoring GABAC receptors to the cytoskeleton to
maintain this clustered distribution (Hanley et al., 1999).
In addition to interacting with MAP1B, r1 subunits can bind to
a glycine transporter splice variant, GLYT-1E/F (Hanley et al.,
2000). These interactions suggest similarities to the organization at
the postsynaptic density of excitatory synapses, where an array of
multimolecular interactions is involved in the anchoring and sig-
naling of AMPA, NMDA, and metabotropic receptors (Ziff, 1997;
Kim and Huganir, 1999). For NMDA receptors, interaction with
the cytoskeletal protein a-actinin-2 tethers the receptor and also
modulates its inactivation (Wyszynski et al., 1997; Zhang et al.,
1998; Krupp et al., 1999). It is unknown whether proteins anchor-
ing inhibitory receptors also modulate channel properties.
Here, we identify the binding site for MAP1B on r1 as a 12
amino acid motif, RI(D/N)THAIDKYSR, at the C-terminal end
of the intracellular loop between transmembrane regions three and
four. Dialysis of retinal bipolar cells with peptides containing this
motif, to competitively disrupt the binding of MAP1B to r1,
decreases the EC50 of GABAC receptors, doubling the amount of
current that they produce at low GABA concentrations. These data
show, for the first time for an inhibitory synapse, that binding of
receptors to the cytoskeleton controls the functional properties of
the receptors.
MATERIALS AND METHODS
Antibodies. MAP1B was detected using Anti-MAP1B, clone AA6 (Sigma,
St. Louis, MO). r1 myc was detected using supernatant from 9E10 hybrid-
oma cells.
Glutathione S-transferase fusion protein production. Glutathione S-trans-
ferase-MAP1B is a fusion of GST with amino acids 460–585 of MAP1B
[similar to the fusion with residues 460–565 used by Hanley et al. (1999)].
GST-GLYT-1E/F contains the C-terminal 58 amino acids of GLYT-1E/F
[GST-clone 6 of Hanley et al. (2000)]. GST-r1 contains the intracellular part
of human r1 between transmembrane domains 3 and 4 (amino acids 355–
454), and GST-r2, a1, b3, and g2 were equivalent constructs. GST fusions of
r1 truncation mutants were constructed by PCR cloning of cDNA fragments
into pGEX-4T3, using primers as follows: r1355–444, 59 sense primer: CGT-
GGATCCGAGTATGCGGCCGTCAAC; 39 antisense primer: GTGGAAT-
TCTCAGTCGATTCTCATGCT; r1355–449, 59 sense primer: CGTGGATC-
CGAGTATGCGGCCGTCAAC; 39 antisense primer: GTAGAATT-
CTCAATCAATGGCGTGGGT; r2, 59 sense primer: GTGGGATCCGAG-
TATGCGGCTGTCAAC; 39 antisense primer: TATGAATTCTCACCTA-
GAGTATTTGTC. Subsequent synthesis and purification of GST fusions
was performed as described by Smith and Johnson (1988).
COS cell transfections. COS cells were cultured at 37°C, 5% CO2, in
DMEM (Life Technologies, Gaithersburg, MD) containing 10% fetal calf
serum (Life Technologies), 2 mM L-glutamine (Life Technologies), peni-
cillin, and streptomycin. Cells were grown to 50–70% confluency, and
transfected by electroporation. Ten milligram cytomegalovirus (CMV)
promoter-driven expression constructs were used per transfection.
Affinity purification (pull-down assay). This was performed from retinal
extract or from transfected COS cells as described previously (Hanley et
al., 1999, 2000). Briefly, retinae or transfected COS cells were lysed in 1%
Triton X-100 lysis buffer, and insoluble material was removed by centrif-
ugation. Lysates were incubated with GST fusion proteins bound to
glutathione-agarose beads at 4°C with rotation for 2 hr. Beads were then
washed three times with lysis buffer and resuspended in SDS-PAGE
sample buffer, and bound proteins were detected by Western blotting.
Site-directed mutagenesis. Mutations were made in a CMV promoter-
driven r1 myc construct (full-length r with the myc tag EQKLISEEDL
between amino acids 4 and 5 of the mature peptide) by the Transformer
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Site-Directed Mutagenesis Kit (Clontech, Cambridge, UK), using the
following mutagenic primers: VSM3KKT: AGCAGCTATAAGAAGAC-
TAGAATCGATACC; RID3FNS: GTGAGCATGTTTAACTCGAC-
CCACGCCATT; THA3VSK: ATGAGAATCGATGTATCAAAAATT-
GATAAATAC; KY3RL: CACGCCATTGATCGTCTATCCAGGATC.
Peptide competition assays. Peptides were synthesized by Altabioscience
and stored at 220°C in DMSO at 40 mg/ml. Pull-down assays were
performed as above in a volume of 1 ml, followed by washing beads once
in lysis buffer. Beads were resuspended in 400 ml lysis buffer, and peptide
was added to varying final concentrations. After rotation at 4°C for 15 min,
the beads were washed an additional three times in lysis buffer and then
resuspended in SDS-PAGE sample buffer, and bound proteins were ana-
lyzed by Western blotting. The normal peptide used containing the (rat)
binding site amino acids had the sequence X-RINTHAIDKYSR (where
X was the antennapedia sequence RQIKIWFQNRRMKWKK, biotin-
ylated at the N terminus; X promotes peptide entry into cells, but this
property was not used in the experiments reported here). The peptide
with the scrambled version of the binding site had the sequence X-
HRTSKINIYRDA. The N-terminally truncated peptide used, THAI-
DKYSR, did not have the antennapedia sequence added.
Isolated bipolar cells. Approximately one-quarter of an isolated retina
from an adult [postnatal day 35 (P35)] rat was incubated at 34°C for 20 min
in 2 ml of solution containing (in mM): NaCl 101, KCl 3.7, NaHCO3 25,
NaH2PO4 10, Na-pyruvate 1, glucose 15, DL-cysteine 10, plus papain
(Sigma P3125, 15 ml /2 ml), then washed four times in extracellular solution
and triturated through a Pasteur pipette, before plating into the recording
chamber.
Retinal slices. Retinal slices from adult (P35) rats were prepared as
described by Werblin (1978) for salamander retina. Briefly, retinal pieces
;2 mm square were laid on Millipore filter paper, ganglion cell side down;
the sclera was gently removed, and the tissue was covered with normal
external solution (lacking CoCl2). The retina was then cut into 200-mm-
thick slices, each still attached to a strip of Millipore, with a hand-operated
razor blade. The slices were rotated through 90°, and the attached Milli-
pore was embedded in lines of Vaseline to hold the slice so that all cell
types were visible for patch-clamping using an upright, fixed-stage micro-
scope. ON-bipolar cells were identified, both before whole-cell clamping
and after filling with Lucifer yellow from the patch pipette, by the location
of their soma in the inner nuclear layer close to the outer plexiform layer,
with dendrites ascending to the outer plexiform layer and an axon descend-
ing to terminate in the inner part of the inner plexiform layer. Most were
probably rod bipolars, or the morphologically similar type 8 and 9 cone ON
bipolars in the classification of Euler and Wa¨ssle (1998). Experiments were
at room temperature (21–25°C).
Electrodes. Electrodes had a resistance of 5–10 MV in external solution.
The series resistance in whole-cell mode was ;25 MV, giving series
resistance voltage errors ,3 mV for currents ,0.1 nA.
Solutions for electrophysiology. Extracellular solution contained (in mM):
NaCl 130, KCl 2.5, MgCl2 2, HEPES 10, glucose 10, CaCl2 2, bicuculline
0.3 (to block GABAA receptors), pH set to 7.4 with NaOH, bubbled with
O2. For experiments on slices, CaCl2 was replaced by CoCl2 (4 mM) to
block synaptic transmission (Euler et al., 1996). Intracellular solution
contained (in mM): KCl 135, CaCl2 0.5, Na2EGTA 5, HEPES 10, MgCl2
2, MgATP 2, pH set to 7.2 with KOH, and Lucifer yellow (di-potassium
salt) 0.2%. In addition, the solution contained 100 mM of either a peptide
including the binding site for MAP1B on r1, X-RINTHAIDKYSR, or a
peptide containing a scrambled version of the binding site X-HRTSKI-
NIYRDA (see above). In some experiments, the peptidase inhibitors
bestatin (10 mM), leupeptin (100 mM), and pepstatin (1 mM) were included
to prevent peptide breakdown, with no significant effect on the results.
Peptide diffusion time to bipolar cell axon terminal. The diffusion constant of
the peptides was estimated as D 5 1.07 3 10 2 10 m 2/sec by scaling the value
for somatostatin (Holladay and Puett, 1976) in proportion to the square root
of the ratio of its molecular weight (1638) to that of the peptides used here
(3945). For an axon of length L 5 50 mm, the diffusion time from the soma
to the axon terminal is ;L 2/2D 5 12 sec. Thus, once inside the cell soma, the
peptides used should equilibrate through the cell relatively quickly. The time
constant for the peptide to equilibrate between the patch pipette and the cell
volume is given by t 5 VRs/(Dr) (Marie and Attwell, 1999), where the cell
volume V is ;850 mm 3 (for a 10-mm-diameter soma, 100 mm total length of
axon plus dendrites of diameter 2 mm, and a synaptic terminal of diameter 3
mm), the series resistance Rs is 25 MV, and the resistivity of the pipette
solution r is 0.8 Vm. With these numbers, t 5 248 sec.
Effect of uptake on GABAC receptor EC50 changes. To quantify how
uptake reduces the GABA concentration outside bipolar cells in retinal
slices, [GABA]o, below the concentration applied in the bulk solution,
[GABA]B, we treat a simplified model of the slice in which the bulk
solution is separated from the extracellular space by a diffusion barrier of
permeability P. GABA enters the extracellular space at a rate:
P~@GABA#!B 2 @GABA#0), (1)
and at equilibrium this must equal the rate of uptake into cells:
U@GABA#0/~@GABA#0 1 KU!, (2)
where U and KU are the maximum rate and Michaelis-Menten constant of
uptake. From Equations 1 and 2:
@GABA#B 5 @GABA#0 1 ~U/P!/$1 1 ~KU/@GABA#0!%. (3)
Thus, when the bulk solution [GABA]B is at a value that makes [GABA]o
equal the EC50, so a half-maximal current is generated:
@GABA#B 5 EC50 1 ~U/P!/$1 1 ~KU/EC50!%. (4)
Because [GABA]o 5 EC50 5 11 mM (measured in isolated cells in cobalt /
zero Ca 21 solution; see Results), when the applied [GABA]B 5 40.4 mM
(mean EC50 measured for the GABA concentration applied to slices; see
Results), and KU ;30 mM for GAT-1 and GAT-3 in rat (Borden et al.,
1994), Equation 4 gives U/P 5 109.6 mM.
For a 32% reduction (from 40.4 mM) of the [GABA]B generating a
half-maximal current, as seen experimentally with the peptide disrupting
the MAP1B-r interaction (see Results), solving Equation 4 gives an EC50
value of 6.9 mM, i.e., reduced from 11 mM by 37%. Thus, fractional changes
in the bulk solution EC50 underestimate fractional changes of the real EC50
by a factor of 32/37 5 0.86, i.e., a 14% underestimate. The presence of
uptake therefore has no effect on the conclusion (see Results) that dis-
rupting the r-MAP1B interaction approximately doubles the current at
low GABA concentrations.
Data analysis
The Hill equation (Eq. 5) was fitted to dose–response data using Sig-
maPlot. Data are presented as mean 6 SEM.
RESULTS
MAP1B binds at the C-terminal end of the r1 subunit
intracellular domain
We have previously demonstrated that MAP1B binds to the
C-terminal quarter of the TM3–TM4 loop of the human r1 sub-
unit, between amino acid residues S434 and R454 (Hanley et al.,
1999). To analyze the binding site further, we constructed two
C-terminal truncations of the GST fusion protein with the full-
length TM3–TM4 loop (GST-r1); we have shown previously that
the GST fusion with the full loop binds MAP1B (Hanley et al.,
1999, their Fig. 2e). These polypeptides, which start at E355 and
terminate at I449 or I444, were tested for interaction with MAP1B
from retinal extract in pull-down assays. The 10 amino acid trun-
cation (E355-I444) showed no MAP1B binding (Fig. 1B), indicating
that crucial residues for the interaction are located within the
region D445-R454. The five amino acid truncation (E355-I449)
showed an extremely low level of MAP1B binding, but it was still
higher than the GST control (Fig. 1C). Taken together, these data
indicate that the residues required for strong binding to MAP1B
are present within the final five amino acids (D450KYSR454) of the
intracellular loop and that there are also contributing residues
among amino acids D445THAI 449.
Identification of residues required for MAP1B binding on
the r1 subunit
To investigate the importance of specific amino acids in r1 for
interaction with MAP1B, we performed site-directed mutagenesis
of a mammalian expression construct encoding full-length human
myc-tagged r1. COS cells transfected with these constructs were
lysed, and binding to GST-MAP1B [containing amino acids 460–
585 of MAP1B (Hanley et al., 1999)] was analyzed in pull-down
assays. Figure 1 demonstrates that residues at the extreme C
terminus of the intracellular r1 loop are crucial for the interaction,
so we mutated residues in this region adjacent to TM4. We have
previously demonstrated that the a1, b3, and g2 subunits of
GABAA receptors do not interact with MAP1B in pull-down
assays (Hanley et al., 1999), so we chose to mutate residues in r1 to
those in a1. Mutations were performed in groups of three residues
as shown in Figure 2A. Of the six most C-terminal residues of this
region, IDKYSR, four are identical in a1 (and also homologous to
a range of other ionotropic GABA receptor subunits), so only two
of these six amino acids were mutated (KY3RL).
The most N-terminal mutation, VSM3KKT, did not affect
binding of r1myc to GST-MAP1B, indicating that these residues
are outside the critical binding site. The RID3FNS and
THA3VSK mutants both display a reduced interaction with GST-
MAP1B, indicating that these residues are important contributors
to the interaction. The most C-terminal mutation, KY3RL, abol-
ished binding to undetectable levels. Thus, of the five most
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C-terminal amino acids shown in Figure 1 to be important for
binding to MAP1B, the lysine–tyrosine motif makes a crucial
contribution.
Although, theoretically, the mutations and truncations described
above could be preventing the binding of MAP1B to r1 by altering
the conformation of a binding site in a distant part of the r1
protein, the results of the experiments described in the next section
make this extremely unlikely: a peptide mimicking the C-terminal
part of the r1 intracellular loop competes with r1 for binding to
MAP1B.
Block of MAP1B binding to r1 by competition with a
binding site peptide
The data above suggest that MAP1B binds to the region RI(D/
N)THAIDKYSR in r1 (where D/N denotes the human/rat se-
quence). To further confirm that this sequence represents the
binding site, we synthesized a peptide containing this sequence
(see Materials and Methods; rat version, as it would be used for
biochemical and electrophysiological experiments on rat tissue, as
described below). To investigate whether this peptide is sufficient
to bind to MAP1B, we performed pull-down assays from rat retinal
extract using GST-r1. If the peptide is capable of binding to
MAP1B, then it will compete with GST-r1 for the binding site on
MAP1B and result in a reduced level of MAP1B binding to
GST-r1 beads. The peptide was added to the assay at varying
concentrations, and the levels of MAP1B were analyzed by West-
ern blotting (Fig. 3A). Peptide at 50 nM had little effect on the
amount of MAP1B bound, but 100 nM significantly reduced the
binding, and at 250 nM no binding was detected to GST-r1. This
competitive inhibition of binding of the human r1 sequence to
MAP1B using a peptide with the rat r1 sequence shows that the
one amino acid difference in these sequences (D/N) does not
prevent binding. A peptide containing a scrambled version of the
binding site, HRTSKINIYRDA, was used as a control (see Ma-
Figure 2. Identification of amino acid residues in the r1 intracellular loop
important for MAP1B binding. Immobilized GST fusion protein corre-
sponding to the r1-binding region of MAP1B was incubated with extracts
of COS cells transfected with mutants of full-length r1 myc in pull-down
assays. Groups of residues in r1 were mutated to the equivalent sequence of
the a1 subunit of GABAA receptors. A, Alignment of extreme C-terminal
regions of intracellular TM3–TM4 loop of r1 and a1 subunits. Amino acid
substitutions are shown in boxes; identical amino acids were not mutated. B,
Binding of r1 myc mutants to GST-MAP1B as determined by Western
blotting. For each construct, in represents the r1 myc present in 5% of the
input, and bd represents protein bound to GST-MAP1B; GST shows lack of
binding of r1 myc to GST alone.
Figure 1. MAP1B binds to the extreme C terminus of the r1 TM3–TM4
intracellular loop. Immobilized GST fusion proteins corresponding to
C-terminal truncations of the r1 intracellular loop were incubated with
retinal extract in pull-down assays. MAP1B binding was determined by
Western blotting. A, Sequences of the GST fusions with the C-terminal half
of r1 intracellular loop (r1 402–454), with a 10 amino acid truncation (355–
454) and a five amino acid truncation (355–449). B, Binding of MAP1B to
the 10 amino acid truncation fusion protein, compared with binding to the
C-terminal half of the intracellular loop r1 402–454. Other lanes show lack of
binding to GST and the input to the assay. in represents the MAP1B
present in 1% of the input. C, Same as B but for the five amino acid
truncated fusion protein.
Figure 3. Competitive inhibition of MAP1B binding to r by peptides. The
peptide containing the motif RINTHAIDKYSR (A) but not that contain-
ing THAIDKYSR (B) competes for MAP1B binding in retinal pull-down
assays. A, Immobilized GST-r1 was incubated first with retinal extract,
followed by 50–250 nM MAP1B binding site peptide or 250 nM scrambled
control peptide. MAP1B bound to beads after this treatment was deter-
mined by Western blotting. B, Same as in A, but with truncated binding-site
peptide. C, Pull-down assay from retinal lysate using immobilized GST
alone or GST fusions of r1, r2, a1, b3, and g2 subunit intracellular loops.
For all panels, lane labeled GST shows no binding of MAP1B to GST alone,
and in represents MAP1B present in 1% of input.
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terials and Methods); this did not compete for MAP1B binding,
even at the highest concentration (250 nM). We also synthesized an
N-terminally truncated peptide corresponding to the sequence
THAIDKYSR and tested this in a similar pull-down assay (Fig.
3B). This peptide was insufficient to compete for MAP1B binding,
demonstrating that, in addition to the KY pair identified above,
one or more of the amino acid residues RIN are required for the
interaction with MAP1B (interaction of r2 with MAP1B, de-
scribed below, suggests that it is the N and not the RI that is
important).
We previously reported that MAP1B does not interact with the
a1, b3, or g2 subunits of GABAA receptors, nor does it interact
with the r2 subunit of GABAC receptors in the yeast two-hybrid
system (Hanley et al., 1999). The sequence of r2 at the extreme C
terminus of the TM3–TM4 loop is FQNTHAIDKYSR, which is
identical to r1 with the exception of FQ. To test the possibility that
r2 can interact with MAP1B, we constructed a GST fusion protein
with the TM3–TM4 loop of r2 and analyzed binding to MAP1B
from retinal extract using a pull-down assay (Fig. 3C). MAP1B
bound to GST-r2 at similar levels to r1 in this assay. This apparent
discrepancy with the previous negative result for r2 in yeast (Han-
ley et al., 1999) is likely to reflect limitations of the yeast two-hybrid
system, because the pull-down assay is performed under more
native conditions. Confirming earlier pull-down and immunopre-
cipitation data (Hanley et al., 1999), in which r2 was not tested,
MAP1B did not interact with a1, b3, and g2 (Fig. 3C).
The glycine transporter GLYT-1E/F and MAP1B bind to
different regions of r1
To investigate whether GLYT-1E/F binds to the same region of r1
as MAP1B or has a different binding site, we performed assays
pulling down myc-tagged r1 from COS cells using GST-MAP1B
and GST-GLYT-1E/F [containing the 58 most C-terminal amino
acids of the bovine transporter (Hanley et al., 2000)]. In each case,
the reactions were treated with 250 nM of the peptide correspond-
ing to the MAP1B binding site, or of the scrambled control pep-
tide, and the binding of r1 to GST-MAP1B and GST-GLYT-1E/F
was determined by Western blotting (Fig. 4A). The binding site
peptide competed for binding to GST-MAP1B, confirming that
this r1 sequence is the site of interaction with MAP1B. However,
the peptide did not compete for binding to GST-GLYT-1E/F,
indicating that the transporter binds to a different region of r1. To
confirm this result, the MAP1B binding site mutants of r1myc were
tested for binding to GST-GLYT-1E/F in pull-down assays from
transfected COS cell lysate (Fig. 4B). All four mutants show a
similar level of binding compared with input, indicating that they
bind equally well to GST-GLYT-1E/F and implying that the
GLYT-1E/F binding site differs from that for MAP1B.
Disrupting the r–MAP1B interaction decreases the EC50
of GABAC receptors
To determine whether the interaction of r subunits with MAP1B
affects the function of GABAC receptors, we whole-cell-clamped
rat retinal bipolar cells. Included in the pipette solution, and thus
dialyzed into the cells, were peptides (100 mM) including the
sequence of the MAP1B-binding domain on r1 or a scrambled
version of it (see Materials and Methods). The aim, as in the
experiments of Figures 3A and 4A, was for the binding site peptide
to compete with endogenous r1 for binding to MAP1B and thus
displace MAP1B from r1, allowing the effect of MAP1B binding
on GABAC receptor-generated currents to be investigated. This
strategy has been used successfully previously to disrupt interac-
tions of endogenous proteins with AMPA receptors and glutamate
transporters (Nishimune et al., 1998; Marie and Attwell, 1999).
Experiments were performed at 260 mV, with the Nernst poten-
tial for Cl2 near 0 mV, so GABA-evoked currents are inward.
Applying GABA either to isolated bipolar cells or to bipolar
cells in retinal slices (see Materials and Methods), in the presence
of bicuculline (300 mM) to block GABAA receptors, generated a
current that was blocked by the GABAC receptor blocker (1,2,5,6-
tetrahydropyridine-4-yl)methylphosphinic acid (TPMPA) (Fig.
5A). Block by TPMPA was only slowly reversible. The response to
30 mM GABA was reduced by 97 6 2% (n 5 4 cells in slices) by 200
mM TPMPA, whereas 2 mM TPMPA reduced the current gener-
ated by 300 mM GABA by 93 6 3% (n 5 2).
In isolated bipolar cells, GABAC receptors showed an EC50 for
GABA of 3.0 6 0.2 mM (n 5 7) (Fig. 5B), similar to the 4.2 mM
obtained by Feigenspan and Bormann (1994a). However, as found
previously (Karschin and Wa¨ssle, 1990), whole-cell-clamped iso-
lated cells stayed healthy for only a few minutes, which is not long
enough to dialyze into the cell the peptide disrupting the
MAP1B-r1 interaction. We therefore studied the effect of disrupt-
ing this interaction in bipolar cells in retinal slices, which could be
clamped for up to 30 min with no deterioration in health. Slice
bipolars were also preferred because the cytoskeleton with which
the GABAC receptors interact is likely to be less disrupted than in
the isolated cells that have been enzyme-treated and triturated.
Cobalt chloride (4 mM) was included in the extracellular solution,
and calcium was omitted, to block synaptic transmission and ensure
that the GABA-evoked currents seen were generated by the re-
corded cell (Euler et al., 1996).
In bipolar cells in situ in slices, the EC50 for GABA applied in
the superfusate was larger than in isolated cells. Dose–response
curves for the GABA-evoked current, I, could be fitted approxi-
mately by the Hill equation:
I 5 Imax@GABA#N/~@GABA#N 1 EC50N!, (5)
where Imax is the maximum current at saturating [GABA], the Hill
coefficient, N, was 1.6, and the EC50 varied between cells (range
26–80 mM) with a mean value of 40.4 6 1.9 mM in 14 cells. Blocking
the mainly neuronal GABA transporter GAT-1 with SKF89976A
(100 mM) (Borden et al., 1994) decreased the EC50 by fourfold (Fig.
5C), making it much closer to the value in isolated cells, showing
that the presence of GABA uptake (Johnson et al., 1996), which
lowers the GABA concentration around the cells within the slice,
is partly responsible for the higher EC50 in slices. The residual
difference in EC50, between slice bipolar cells with GAT-1 blocked
and isolated bipolar cells, may reflect the use of solution containing
Figure 4. GLYT-1E/F and MAP1B interact with different regions of the
r1 intracellular loop. A, Immobilized GST-GLYT-1E/F or GST-MAP1B
were incubated first with extract of COS cells transfected with r1 myc,
followed by 250 nM of the MAP1B binding site peptide (1) containing
RINTHAIDKYSR, or of the peptide containing a scrambled version (2)
of the binding site. r1 myc bound to beads after this treatment was deter-
mined by Western blotting. GST shows lack of binding of r1 myc to GST
alone, and in represents the r1 myc present in 5% of the input. B, Immobi-
lized GST-GLYT-1E/F was incubated with extracts of COS cells trans-
fected with mutants of r1 myc subunit in pull-down assays. Groups of
residues in r1 were mutated to the equivalent sequence of a1 subunit of
GABAA receptors (Fig. 2). For each construct, in represents the r1
myc
present in 5% of the input, and bd represents protein bound to GST-
MAP1B; GST shows lack of binding of r1 myc to GST alone.
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cobalt and zero calcium to block synaptic transmission in the slice
(Euler et al., 1996): in five isolated bipolar cells this solution
increased the EC50 to 11 6 2 mM [data not shown; cf. Kaneda et al.
(1997)]. Mathematical analysis (see Materials and Methods) shows
that, although uptake increases the EC50 measured in the slice, the
fractional change of EC50 induced by disrupting the MAP1B-r1
interaction is similar to that which would be measured if uptake
were absent (the fractional change is underestimated by 14%).
When the peptide mimicking the MAP1B binding site was in-
troduced into slice bipolar cells, the GABA responses changed with
time after starting whole-cell clamping, with low GABA doses
producing an increased current at later times but the response to
high doses changing little (Fig. 6A,B). This corresponds to a
decrease of EC50 of the dose–response curve (Fig. 6C). By contrast,
including the scrambled peptide in the pipette resulted in either no
time-dependent change of the GABA responses or a reduction of
the fractional response to low [GABA] (Fig. 6D).
To quantify the change of GABAC receptor properties, we fitted
Equation 5 to dose–response data obtained at different times after
starting whole-cell clamping, to derive the EC50 and Imax for the
receptors. The maximum current showed no significant difference
in behavior when the active or scrambled peptides were introduced
(Fig. 7A). Both showed a slow decrease with time that may reflect
an alteration of internal milieu by the non-peptide components of
the pipette solution (cf. Feigenspan and Bormann, 1994b). To
quantify the change of receptor sensitivity, for each cell we nor-
malized the EC50 values by the EC50 measured at the start of
whole-cell recording. This procedure was adopted to remove vari-
Figure 5. GABAC receptor-evoked currents in retinal bipolar cells with no
peptide included in the pipette solution. A, Membrane current of a cell in
a slice, clamped to 260 mV, during repeated application of 30 mM GABA
in the presence of 300 mM bicuculline to block GABAA receptors. The
GABAC receptor blocker TPMPA (200 mM) greatly reduces the response to
GABA. This block was only slowly removed on washing out TPMPA. B,
Dose–response curve for the application of GABA to isolated bipolar cells
in the presence of 300 mM bicuculline (normalized to the response to 10 mM
GABA in each cell and then rescaled to a saturating response of 1). Curve
is a Hill equation (Eq. 5) with n 5 1.6 and a mean EC50 of 3 mM. Data from
seven cells. C, Dose–response curves for five bipolar cells in slices, in the
presence of 300 mM bicuculline and 4 mM Co 21/0 mM Ca 21, initially in
normal conditions (control) and then in the presence of 100 mM
SKF89976A (GAT-1 blocked). Hill equations through the data have n 5 1.6
and an EC50 of 51 mM in control conditions (mean value was 51.0 6 3.7 mM)
and 13.4 mM with GAT-1 blocked (mean value was 13.4 6 2.2 mM).
Figure 6. Effect of dialysis with MAP1B binding site peptide on the
GABA dose–response curve in retinal bipolar cells. A, Specimen current
responses to different GABA concentrations (in the presence of bicucul-
line) 5 min after going to whole-cell mode, with the binding site peptide in
the pipette. B, Dose–response curve in the same cell as A, 25 min after
starting whole-cell clamping. Responses in A and B have been scaled to be
the same for 300 mM GABA, to compensate for a slight decline with time
(Fig. 7A), and to facilitate comparison of the dose dependence of the
responses. The relative responses to low doses of GABA are much larger in
B than in A. C, Dose–response data from A and B, normalized to the
current produced by 300 mM GABA, fitted with the Hill equation (Eq. 5)
with a Hill coefficient of 1.6. At 5 min the EC50 is 79 mM; at 25 min it is 31
mM. d, Specimen dose–response data as in C, but from a cell clamped with
the scrambled peptide in the pipette. Fitting the Hill equation (with a Hill
coefficient of 1.6) gives an EC50 of 37 mM at 5 min and 53 mM at 25 min after
starting whole-cell clamping.
Figure 7. Time-dependent changes in the properties of GABAC receptors
induced by competitive removal of MAP1B binding. Maximum current (A)
and EC50 (B) derived from fitting the Hill equation (Eq. 5) to dose–
response data measured at different times after starting whole-cell clamping
with pipette solution containing the MAP1B binding site peptide (F) or a
scrambled version of it (E). Data from each cell were normalized to their
values measured 5 min after starting whole-cell clamping, before averaging
for these graphs. Data in A are not significantly different for the two
peptides. The p values in B are from two-tailed t tests. Eight to thirteen cells
contribute to each data point.
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ability in the initial value of the EC50 (see above) and thus allow us
to monitor solely the time-dependent change of EC50 produced by
the peptide. Figure 7B shows that the binding site peptide led to a
decrease of EC50, whereas the scrambled peptide produced no
significant change. The data for the two peptides differ significantly
after 15 and 25 min recording. Furthermore, this difference is
underestimated by our data, because the “initial” value of EC50 by
which the subsequent data were normalized was measured 5 min
after starting whole-cell clamping, by which time the binding site
peptide may already have had some effect. The time constant for
filling of the cell by the dialyzed peptides is estimated to be ;4 min
(see Materials and Methods), so the time course of the changes
seen with the binding site peptide in Figure 7B may reflect both this
filling time and the time needed for competitive displacement of
endogenous r1 from MAP1B by the peptide.
The mean data in Figure 7B show that the binding site peptide
reduces the EC50 at 25 min after starting whole-cell clamping to
68% of its value with the scrambled peptide, implying a 1.9-fold
increase of the current evoked by low doses of GABA (e.g., see
specimen data in Fig. 6C). Thus, in the absence of the dialyzing
peptide, the interaction with MAP1B roughly halves the size of the
current that low doses of GABA generate.
Glycine does not alter GABAC responses
Although the cellular location of GLYT-1E/F transporters is not
known, their interaction in vitro with r1 suggests that, if these
transporters are present in bipolar cells, the rate of glycine uptake
could alter GABAC receptor properties (or vice versa). However,
we found that applying 300 mM glycine (in the presence of 10 mM
strychnine to block glycine receptors) had no effect on the GABAC
response of retinal bipolar cells to 30 mM GABA (subsaturating so
that we might observe changes in either EC50 or maximum current;
five cells; data not shown). No glycine uptake current was detect-
able in the bipolar cells, so we could not test the effect of GABAC
receptor activation on glycine uptake.
DISCUSSION
Our analysis of the binding site for MAP1B on the r1 subunits of
GABAC receptors suggests that MAP1B binds to the sequence
RI(D/N)THAIDKYSR, where D/N denotes the human/rat se-
quence. Of these residues, the section KY is crucial, because
mutating it prevents binding (Fig. 2B) but is not sufficient, because
the truncated peptide THAIDKYSR does not prevent binding
(Fig. 3B) and because mutating THA or RID to the homologous
residues in a1 subunits also reduces binding, suggesting that these
residues also contribute to binding. Binding occurs whether the
residue present at the D/N position is either D or N, because the rat
sequence peptide (N) competes well with human r1 (D) for binding
to MAP1B (Fig. 3A). This may be allowed because although D is
charged whereas N is polar, they both have small side chains. The
more C-terminal residues ID and SR may contribute to binding but
are present in a and b subunits of GABAA receptors, which do not
bind MAP1B. The binding site may not extend N-terminally be-
yond R443 (in the human sequence) because r1myc binds efficiently
to GST-MAP1B even when V440SM442 are mutated to KKT.
The motif RI(D/N)THAIDKYSR in its entirety is not found in
any other proteins in the database, but the r2 subunit has an
equivalent 12 amino acid motif of FQNTHAIDKYSR, which also
binds MAP1B in pull-down assays (Fig. 3C). The first two amino
acids of these sequences differ, suggesting a minimal binding motif
of NTHAIDKYSR. The r3 subunit, which was not analyzed,
contains the sequence LENNHVIDTYSR. The major GABAA
receptor subunits do not show high homology with r in this region,
the most similar being the b subunits (e.g., b3: LTDVNAID-
RWSR). The absence of MAP1B binding to GABAA receptors,
which has been demonstrated by pull-down assay and immunopre-
cipitation from retina (Hanley et al., 1999), is consistent with these
differing sequences. GABAA receptors may be anchored to the
cytoskeleton through the tubulin binding proteins gephyrin and
GABARAP (Essrich et al., 1998; Wang et al., 1999), although
direct binding of gephyrin to GABAA receptor subunits has not
been shown. The existence of the different tethering molecules for
GABAA and GABAC receptors may help to explain their specific
location at different synapses and their lack of colocalization in
bipolar cells (Koulen et al., 1998). Interestingly, GABARAP shows
31% identity to light-chain-3 of MAP1A and MAP1B, and it binds
to g2 subunits in a C-terminal region of their TM3–TM4 loop at an
equivalent position to the MAP1B binding site on r1/r2.
Dialyzing retinal bipolar cells with a peptide mimicking the
MAP1B binding motif, which we have shown to competitively
disrupt MAP1B-r1 binding (Fig. 3A), led to a 32% decrease in the
EC50 of the cells’ GABAC receptors, which is sufficient to approx-
imately double the GABA-evoked current at low GABA concen-
trations (Fig. 6C). At the same time, there was no change of the
maximum GABA-evoked current, suggesting that binding of
MAP1B to r does not alter the number of receptors in the mem-
brane (in contrast to the effect of binding of NSF to AMPA
receptors) (Nishimune et al., 1998; Luscher et al., 1999). It is likely
that the binding of MAP1B to r alters the energetics of the
conformation changes that occur when the receptor binds GABA
and opens its channel, and in this way MAP1B alters the EC50. A
similar phenomenon has been observed for glutamate transporters
(Marie and Attwell, 1999). Because MAP1B aggregates r1 sub-
units (Hanley et al., 1999), it is possible that, in addition to chang-
ing the EC50, disruption of the MAP1B-r interaction may allow
GABAC receptors to disperse to a more extrasynaptic location;
however, it is likely that the change in EC50 occurs as soon as the
r subunits detach from MAP1B.
In the retina, the feedback inhibition of bipolar cells by amacrine
cells, mediated largely by GABAC receptors, increases the dynamic
range of the ganglion cells and produces temporal and spatial
shaping of the visual signal, making signals more transient and
enhancing edge detection (Dong and Werblin, 1998; Jacobs and
Werblin, 1998; Euler and Masland, 2000; Roska et al., 2000; Shields
et al., 2000). GABAC receptors produce long duration IPSCs in
bipolar cells when amacrine cells release GABA (Lukasiewicz and
Shields, 1998; Shields et al., 2000). Lowering the EC50 of GABAC
receptors is expected to increase the duration of the synaptic
current in the following circumstances. First, if after the peak of
the IPSC the extracellular GABA concentration falls slowly com-
pared with the receptor and channel gating kinetics, then if the
EC50 is lower the GABA concentration will have to fall to a lower
level before the receptors can deactivate, which will take longer.
Alternatively, if the GABA concentration falls to zero rapidly
(compared with the GABA unbinding/channel gating kinetics),
then a lower EC50 is predicted to prolong the IPSC decay provided
that the effect of MAP1B on the EC50 is mediated by an alteration
of the rate constant for GABA unbinding or for channel opening or
closing [but there will be no effect on the IPSC decay if the EC50 is
lowered by increasing the GABA binding rate (cf. Jones et al.,
1998]. To illustrate this quantitatively, we performed calculations
based on the GABAC receptor kinetic scheme of Chang and Weiss
(1999) with channel opening occurring when three GABA mole-
cules are bound. Individual rate constants were altered to decrease
the EC50 by 32%, as we found [in the Chang and Weiss (1999)
model, we used an absolute change from 0.83 mM, when interacting
with MAP1B, to 0.56 mM (their standard parameters) in the ab-
sence of MAP1B]. Producing this EC50 change by decreasing the
GABA unbinding rate, decreasing the channel closing rate, or
increasing the channel opening rate led to the IPSC decay time
constant being increased by 40, 114, or 89%, respectively.
A prolongation of the IPSC will increase the spatiotemporal
filtering mediated by this feedback synapse. In addition, doubling
the GABAC receptor-mediated current at the low GABA concen-
trations likely to be continually present in the retina, where most
synapses mediate graded potentials and are tonically active, would
produce an extra tonic inhibition of glutamate release from bipolar
cell synaptic terminals and thus decrease ganglion cell firing. For
such an alteration of information processing to occur, for example
during light adaptation, the interaction between MAP1B and r
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subunits would have to be modulated. This could potentially occur
by phosphorylation of either of the serine residues in the r1
sequence, which are within or flank the MAP1B binding site
defined above (S441 and S453 in the human sequence; S441 is a
consensus site for PKC phosphorylation).
The MAP1B binding site peptide does not compete for binding
of r1 to the C-terminal tail of the glycine transporter GLYT-1E/F,
and none of the MAP1B binding site mutations in r1myc affected
binding to GST-GLYT-1E/F (Fig. 4), indicating that the trans-
porter binds to a region on r1 distinct from the MAP1B binding
site. This suggests that MAP1B and GLYT-1E/F may be able to
interact with r1 simultaneously, perhaps allowing r1 and GLYT-
1E/F to be anchored to the cytoskeleton as a complex. The location
of GLYT-1E/F in the retina has not yet been determined: previous
studies of glycine transporter location have used antibodies raised
against transporter C and N termini, which are not present in
GLYT-1E/F. Because some bipolar cells accumulate glycine, but
not via GLYT-1A or -B (Pow and Hendrickson, 1999), it is possible
that GLYT-1E/F is colocalized in bipolar cell synaptic terminals
with r1 subunits. Application of glycine had no effect on GABAC
receptor-mediated currents, implying that if GLYT-1E/F trans-
porters are present, their linkage to r1 subunits does not result in
transporter activity modulating GABAC receptor properties [it also
shows that the potentiation of homomeric r1 receptor activity by
glycine seen in oocyte expression experiments (Calvo and Miledi,
1995) does not occur for bipolar cell GABAC receptors]. We have
been unable to test whether activation of GABAC receptors mod-
ulates glycine uptake into bipolar cells, because the glycine uptake
present in these cells is too small to generate a detectable current.
In summary, by identifying a motif for MAP1B binding to r
subunits, we have shown for the first time that inhibitory GABAC
receptors have their EC50 modulated by attachment to the cy-
toskeleton and that they can potentially interact simultaneously
with MAP1B and with a glycine transporter. This suggests that the
postsynaptic density at inhibitory synapses is likely to comprise as
complicated a web of interacting receptors and signaling proteins
as occurs at excitatory synapses (Ziff, 1997; Kim and Huganir,
1999).
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